325775-36-8

Basic information

• Product Name: 1-BOC-3-CBZ-AMINOPYRROLIDINE
• Synonyms: 1-BOC-3-CBZ-AMINOPYRROLIDINE
• CAS NO: 325775-36-8
• Molecular Formula: C₁₇H₂₄N₂O₄
• Molecular Weight: 320.17
• Mol File: 325775-36-8.mol

Chemical Properties

• Boiling Point: 458.135 °C at 760 mmHg
• Flash Point: 230.872 °C
• Appearance: /
• Density: 1.174 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-BOC-3-CBZ-AMINOPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3-CBZ-AMINOPYRROLIDINE(325775-36-8)
• EPA Substance Registry System: 1-BOC-3-CBZ-AMINOPYRROLIDINE(325775-36-8)

Safety Data

• Hazardous Substances Data: 325775-36-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-Boc-3-Cbz-aminopyrrolidine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex molecular structures that possess therapeutic potential.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Boc-3-Cbz-aminopyrrolidine is utilized as a building block for creating a variety of biologically active molecules, highlighting its importance in the development of new chemical entities with potential applications in medicine and other industries.
Used in Drug Discovery:
1-Boc-3-Cbz-aminopyrrolidine is employed as a component in drug discovery processes, where its unique properties can be leveraged to design and develop new medicinal agents with improved efficacy and selectivity.
Used in the Synthesis of Natural Products:
1-Boc-3-Cbz-aminopyrrolidine is also used in the synthesis of natural products, contributing to the development of novel bioactive compounds that can be used for various therapeutic applications.

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 186550-13-0 3-amino-1-(t-butoxycarbonyl)pyrrolidine 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 100-51-6 benzyl alcohol 
• 501-53-1 benzyl chloroformate 
• 122684-33-7 methyl 1-tert-butoxycarbonyl-3-pyrrolidinecarboxylate 

Downstream Products

• 887587-20-4 tert-butyl 3-(N-n-propylamino)pyrrolidine-1-carboxylate 
• 887587-15-7 3-ethylamino-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 454712-26-6 tert‐butyl 3‐(methylamino)pyrrolidine‐1‐carboxylate 
• 503067-83-2 1-(cyclopropylmethyl)-N-methylpyrrolidin-3-amine 
• 762285-90-5 3-[(biphenyl-4-carbonyl)-amino]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1026571-79-8 3-benzenesulfonylamino-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Discovery of quinazoline-2,4(1: H,3 H)-dione derivatives as novel PARP-1/2 inhibitors: Design, synthesis and their antitumor activity

Novel quinazoline-2,4(1H,3H)-dione derivatives bearing a 3-amino pyrrolidine moiety were designed and synthesized as PARP-1/2 inhibitors. Structure-activity relationships were examined which revealed a number of potent PARP-1/2 inhibitors with moderate se

3-amino nafoxidine-containing quinazoline ketone PARP (Poly Adenosine Diphosphate Ribose Polymerase)-1/2 inhibitor as well as preparation method, medicinal composition and application thereof

The invention discloses a novel 3-amino nafoxidine-containing quinazoline-2,4(1H, 3H)-diketone PARP-1/2 (Poly Adenosine Diphosphate Ribose Polymerase) inhibitor as well as a preparation method, a medicinal composition and application thereof. Specifically, the invention relates to a 3-amino nafoxidine-containing quinazoline-2,4(1H, 3H)-diketone derivative and a medicinal salt thereof of formula (I) as shown in the specification, a preparation method thereof, a composition with one or more such compounds, preparation of the compounds, and application thereof in preparing medicines for preventing and/or treating PARP-1/2 related diseases.

Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in?vivo anti-tumor activity

Novel 1H-benzo[d]immidazole-4-carboxamide derivatives bearing five-membered or six-membered N-heterocyclic moieties at the 2-position were designed and synthesized as PARP-1 inhibitors. Structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values in the single or double digit nanomolar level. Some potent PARP-1 inhibitors also had similar inhibitory activities against PARP-2. Among all the synthesized compounds, compound 10a and 11e displayed strong potentiation effects on temozolomide (TMZ) in MX-1?cells (PF50?=?7.10, PF50?=?4.17). In?vivo tumor growth inhibition was investigated using compound 10a in combination with TMZ, and it was demonstrated that compound 10a could strongly potentiate the cytotoxicity of TMZ in MX-1 xenograft tumor model. Two co-crystal structures of compounds 11b and 15e complexed with PARP-1 were achieved and demonstrated a unique binding mode of these benzo-imidazole derivatives.

HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS

The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L

Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC50 values of 0.37 and 0.45 μM, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found to be a potent inhibitor of cathepsins K and L with a Ki value of 50 nM for cathepsin K. Replacement of the 1-cyanopyrrolidine of compound 2 by a 1-cyanoazetidine increased the potency of the inhibitor by 10-fold. This increase in potency is probably due to an enhanced chemical reactivity of the compound toward the thiolate of the active site of the enzyme. This is demonstrated when the assay is performed in the presence of glutathione at pH 7.0 which favors the formation of a GSH thiolate anion. Under these assay conditions, there is a loss of potency in the 1-cyanoazetidine series due to the formation of an inactive complex between the GSH thiolate and the 1-cyanoazetidine inhibitors. 1-Cyanopyrrolidinyl inhibitors exhibited time-dependent inhibition which allowed us to determine the association and dissociation rate constants with human cathepsin K. The kinetic data obtained showed that the increase of potency observed between different 1-cyanopyrrolidinyl inhibitors is due to an increase of kon values and that the association of the compound with the enzyme fits an apparent one-step mechanism. 13C NMR experiments performed with the enzyme papain showed that compound 2 forms a covalent isothiourea ester adduct with the enzyme. As predicted by the kinetic analysis, the addition of the irreversible inhibitor E64 to the enzyme-cyanopyrrolidinyl complex totally abolished the signal of the isothiourea bond as observed by 13C NMR, thereby demonstrating that the formation of the covalent bond with the active site cysteine residue is reversible. Finally, compound 2 inhibits bone resorption in an in vitro assay involving rabbit osteoclasts and bovine bone with an IC50 value of 0.7 μM. 1-Cyanopyrrolidine represents a new class of nonpeptidic compounds that inhibit cathepsin K and L activity and proteolysis of bone collagen.